A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO)-Reference-Cited by-同舟云学术

A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO)

Published:2016-05-20 Issue:2 Volume:5 Page:e88
ISSN:1929-0748
Container-title:JMIR Research Protocols
language:en
Short-container-title:JMIR Res Protoc

Author:

Zdenkowski Nicholas^ORCID,Butow Phyllis^ORCID,Hutchings Elizabeth^ORCID,Douglas Charles^ORCID,Coll Joseph R^ORCID,Boyle Frances M^ORCID

Publisher

JMIR Publications Inc.

Subject

General Medicine

Reference48 articles.

1. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

2. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

3. Exploring Decision-Making about Neo-adjuvant Chemotherapy for Breast Cancer

4. Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer

5. Advocates' Perspective: Neoadjuvant Chemotherapy for Breast Cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility study of a multimodal prehabilitation programme in women receiving neoadjuvant therapy for breast cancer in a major cancer hospital: a protocol;BMJ Open;2024-03

2. Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration;Medical Decision Making;2021-06-19

3. Patient-reported outcomes with neoadjuvant vs adjuvant systemic therapy for operable breast cancer;The Breast;2019-08

4. Assessing the quality and communicative aspects of patient decision aids for early-stage breast cancer treatment: a systematic review;Breast Cancer Research and Treatment;2019-07-24

Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments

;Patient Preference and Adherence;2019-04